The Oncology Institute, Inc.TOINASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +16.88% | +10.29% | +21.53% | +36.70% | +41.58% |
| Gross Profit Growth | +1.79% | +44.11% | +34.35% | +31.70% | +8.10% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.98% | +3.86% | +1146.90% | +1190.63% | +1241.04% |
| Weighted Average Shares Diluted Growth | +2.98% | +3.86% | +1146.90% | +1190.63% | +1241.04% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -1642.12% | -22.77% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -1183.87% | -10.61% |
| Receivables Growth | +13.45% | -16.00% | +2.38% | +9.33% | +21.85% |
| Inventory Growth | -26.60% | +6.53% | +39.43% | +86.84% | +68.09% |
| Asset Growth | -17.46% | -19.82% | -11.03% | -8.69% | -4.67% |
| Book Value per Share Growth | -93.89% | -88.18% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +2.91% | -14.63% | -18.83% | -77.75% | -78.65% |
| R&D Expense Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +0.00% | +0.00% | +0.00% | +0.00% | +12.62% |